Hebei Changshan Biochemical Pharmaceutical Balance Sheet Health
Financial Health criteria checks 2/6
Hebei Changshan Biochemical Pharmaceutical has a total shareholder equity of CN¥1.8B and total debt of CN¥1.6B, which brings its debt-to-equity ratio to 92.6%. Its total assets and total liabilities are CN¥4.7B and CN¥2.9B respectively.
Key information
92.6%
Debt to equity ratio
CN¥1.64b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥314.22m |
| Equity | CN¥1.77b |
| Total liabilities | CN¥2.91b |
| Total assets | CN¥4.69b |
Recent financial health updates
Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30
Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Recent updates
Calculating The Intrinsic Value Of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255)
Oct 30Subdued Growth No Barrier To Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) With Shares Advancing 55%
Oct 08Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Is Carrying A Fair Bit Of Debt
Sep 30Pinning Down Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) P/S Is Difficult Right Now
Jul 25Is Hebei Changshan Biochemical Pharmaceutical (SZSE:300255) Using Too Much Debt?
May 27Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (SZSE:300255) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
Apr 15Hebei Changshan Biochemical Pharmaceutical Co., Ltd.'s (SZSE:300255) 30% Share Price Surge Not Quite Adding Up
Mar 01Financial Position Analysis
Short Term Liabilities: 300255's short term assets (CN¥2.2B) exceed its short term liabilities (CN¥2.0B).
Long Term Liabilities: 300255's short term assets (CN¥2.2B) exceed its long term liabilities (CN¥939.9M).
Debt to Equity History and Analysis
Debt Level: 300255's net debt to equity ratio (74.9%) is considered high.
Reducing Debt: 300255's debt to equity ratio has increased from 38.7% to 92.6% over the past 5 years.
Debt Coverage: 300255's debt is not well covered by operating cash flow (18.7%).
Interest Coverage: Insufficient data to determine if 300255's interest payments on its debt are well covered by EBIT.